JP2023107764A - Composition for improving aftereffect of viral infection and/or inhibiting deterioration of symptom - Google Patents

Abstract

To provide a novel composition for improving aftereffect symptoms of viral infection that does not involve side effects and can be readily produced.SOLUTION: The present invention provides a composition that includes a hydrogen gas-containing gas as an active ingredient and is for improving aftereffect symptoms of viral infection in a patient suffering from the aftereffect of viral infection, such as pulmonary fibrillization, fatigue, malaise, breathlessness, dyspnea, and/or a deteriorating activity level caused by these symptoms, and/or a method for improving symptoms such as a deteriorating activity level caused by these symptoms.SELECTED DRAWING: None

Description

The present invention ameliorate symptoms of sequelae of viral infections, such as fatigue, headache, physical pain, poor thinking, poor concentration, and/or decreased activity level associated with these symptoms. and/or to a composition for suppressing aggravation of symptoms.
The present invention also relates to methods for ameliorating sequelae and/or suppressing deterioration of symptoms of viral infections.

The aftereffects of viral infections such as influenza virus and novel coronavirus infection (COVID-19) are attacked by severe general malaise, long-term fatigue, extreme malaise that worsens after exertion, slight fever, headache, and muscle pain. , Weakness, cognitive dysfunction, sleep without feeling of recovery, and dizziness on standing up.
The aftereffects of viral infections such as influenza virus and novel coronavirus infection (COVID-19) are characterized by systemic pain of unknown cause as the main symptom. The pain extends to enthesitis, muscles, joints, etc., and presents symptoms of severe pain spreading from the trunk and extremities throughout the body.
The aftereffects of viral infections such as the influenza virus and the new coronavirus infection (COVID-19) are difficult to describe, so even if you recover from the virus infection, you may not be able to perform healthy social activities at times. It has the feature that it cannot be sent. However, the pathological mechanism of the sequelae of viral infections such as influenza virus and novel coronavirus infection (COVID-19) is unknown, and there is no cure.
On the other hand, hydrogen, which is the active ingredient of the present invention, has antioxidant reactivity that suppresses oxidative stress caused by reactive oxygen species, and has been shown to improve chronic bronchitis and obstructive pulmonary bronchitis in studies using mice. There is (Patent Document 1). However, there is no precedent that hydrogen is effective in improving the aftereffects of viral infections.

Patent No. 6628449

An object of the present invention is to provide a new composition for improving symptoms of sequelae of viral infections and/or suppressing aggravation of symptoms, which can be easily produced without side effects.
In recent years, it has been proposed that hydrogen molecules may suppress pneumonia by scavenging hydroxyl radicals generated inside the mitochondria of cells, and may be effective against pneumonia (Patent Document 1). However, it has not been reported whether the aftereffects of viral infection are improved and/or the exacerbation of symptoms is suppressed when inhaling, inhaling, or drinking gas containing hydrogen gas. do not have.

As a result of intensive research, the present inventors unexpectedly found that hydrogen gas-containing gas improves specific symptoms of sequelae of viral infections and/or suppresses aggravation of symptoms.
Accordingly, the present invention includes the following features.
(1) A composition for ameliorating symptoms and/or suppressing aggravation of the aftereffects of a viral infection in a patient suffering from the aftereffects of a viral infection, comprising a hydrogen gas-containing gas as an active ingredient.
(2) the virus of the viral infection is coronavirus, novel coronavirus, influenza virus, norovirus, cytomegalovirus, yellow fever virus, herpes virus, measles virus, rubella virus, varicella virus, Ebola virus, Marburg virus, adenovirus The composition according to (1), which is one or more viruses selected from the group consisting of viruses, papillomavirus, immunodeficiency virus, hepatitis B virus, hantavirus, and mutant strains of these viruses. It is a thing.
(3) Symptoms of sequelae of the virus infection include at least pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, slight fever, muscle pain, hypoesthesia, arthralgia, chest discomfort, Chest pain, sore throat, headache, dull headache, body pain, general pain, weakness, cognitive dysfunction, memory impairment, language search difficulty, gastrointestinal disorder, abdominal pain, poor concentration, dizziness when standing up, weakness, weakness Regular body temperature, chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, tinnitus, confusion, sleep disturbance, lightheadedness, dizziness, loss of appetite, The composition according to (1) or (2) comprising weakness, bradycardia, decreased blood pressure, nausea, persistent cough, brain fog, rash, and/or decreased activity level associated with these symptoms.
(4) The composition according to any one of (1) to (3), wherein the hydrogen gas-containing gas has a hydrogen concentration of greater than zero (0) and not more than 18.5% by volume.
(5) The composition according to any one of (1) to (4), wherein said composition is administered to said patient by inhalation.
(6) A method for producing the composition according to any one of (1) to (5) above, wherein the composition is produced using a hydrogen gas generator. be.

According to the present invention, at least pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, slight fever, muscle pain, and hypoesthesia caused by the aftereffects of viral infections caused by hydrogen gas inhalation, inhalation, etc. , arthralgia, chest discomfort, chest pain, sore throat, headache, dull headache, body pain, general pain, weakness, cognitive dysfunction, memory impairment, language search difficulty, gastrointestinal disorder, abdominal pain, decreased concentration, Dizziness on standing, weakness, irregular body temperature, chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, tinnitus, confusion, sleep disturbance, Significant improvement and/or worsening of lightheadedness, dizziness, loss of appetite, weakness, bradycardia, hypotension, nausea, persistent cough, brain fog, rash, and/or decreased activity levels associated with these symptoms can be suppressed.

The present invention will now be described in more detail.
1. Aftereffects of viral infections and symptoms thereof The patients with viral infections in the present invention include coronaviruses including the novel coronavirus that caused COVID-19, influenza viruses, noroviruses, cytomegaloviruses, yellow fever viruses, and herpes viruses. , measles virus, rubella virus, varicella virus, Ebola virus, Marburg virus, adenovirus, papilloma virus, immunodeficiency virus, hepatitis B virus, hantavirus, and other pathogenic viruses. In addition, the aftereffects of viral infections refer to symptoms that remain even after infection with these viruses causes viral infections, which are cured. The sequelae of viral infection in the present invention are clearly distinguished from the symptoms that develop during viral infection. Therefore, a patient with sequelae of a viral infection in the present invention refers to a patient whose viral infection has been confirmed by a viral test such as PCR, but whose virus has been largely eliminated from the body thereafter.
However, in the case of retroviruses such as immunodeficiency virus and papillomavirus, symptoms of viral infection were relieved by suppression of viral expression after symptoms of viral infection developed due to viral expression, but retroviral symptoms including the sequelae of viral infections in which the gene is integrated into nucleic acids such as host chromosomes. In addition, the aftereffects of the viral infection of the present invention include the aftereffects of the virus, such as herpes virus, in which the virus is not completely removed, and the virus remains latent in the body after the viral infection develops and is cured. .

The sequelae of viral infections are symptoms that appear after infection with various pathogenic viruses, and the symptoms include pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, slight fever, and muscle pain. , Hypoesthesia, Arthralgia, Chest discomfort, Chest pain, Sore throat, Headache, Heavy head, Body pain, General pain, Weakness, Cognitive dysfunction, Memory disorder, Language search difficulty, Gastrointestinal disorder, Abdominal pain, Concentration Weakness, dizziness on standing, weakness, irregular body temperature, chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, ringing in the ears, confusion, Sleep disturbances, lightheadedness, dizziness, loss of appetite, weakness, bradycardia, hypotension, nausea, persistent cough, brain fog, rashes, and/or decreased activity levels associated with these symptoms.

Viruses associated with sequelae of viral infections in the present invention include, for example, coronaviruses including the novel coronavirus that caused COVID-19, influenza viruses, noroviruses, cytomegaloviruses, yellow fever viruses, herpes viruses, and measles viruses. , rubella virus, varicella virus, Ebola virus, Marburg virus, adenovirus, papillomavirus, immunodeficiency virus, hepatitis B virus, hantavirus, and other pathogenic viruses.

The after-effects of viral infections are often that even if the person complains of physical symptoms, no abnormalities are confirmed by examination. Symptoms such as abnormal sensory sensitivity may also occur.

2. A composition for improving sequelae of viral infection and/or suppressing worsening of symptoms According to the first aspect, the present invention provides a viral infection in patients with sequelae of viral infection, which contains a hydrogen gas-containing gas as an active ingredient. At least pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, slight fever, muscle pain, hypoesthesia, arthralgia, chest discomfort, chest pain, sore throat caused by sequelae of disease , headache, dull headache, body pain, general pain, weakness, cognitive impairment, memory impairment, language search difficulty, gastrointestinal disorder, abdominal pain, poor concentration, dizziness on standing up, weakness, irregular body temperature, chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, tinnitus, confusion, sleep disturbance, lightheadedness, dizziness, loss of appetite, weakness, bradycardia, Compositions are provided for ameliorating and/or inhibiting exacerbation of symptoms including hypotension, nausea, persistent cough, brain fog, rashes, and/or reduced activity levels associated with these symptoms.

As used herein, "hydrogen", which is the active ingredient of the composition of the present invention, is molecular hydrogen (ie, gaseous hydrogen), and is simply referred to as "hydrogen" or "hydrogen gas" unless otherwise specified. Also, the term "hydrogen" as used herein refers to H ₂ , D ₂ (deuterium), HD (hydrogen deuteride), or a mixture thereof by molecular formula. Although _D2 is expensive, it is known to have a stronger superoxide scavenging effect than _H2 . Hydrogen that can be used in the present invention is _H2 , _D2 (deuterium), HD (deuterium), or mixtures thereof, preferably _H2 , or instead of _H2 , or _D2 and/or HD may be used mixed with _H2 .

The gas containing hydrogen gas is preferably air containing hydrogen gas or a mixed gas containing hydrogen gas and oxygen gas. The hydrogen gas concentration of the hydrogen gas-containing gas is greater than zero (0) and 18.5% by volume or less, preferably 10% by volume or less, for example, 0.1 to 18.5% by volume, preferably 1-18.5% by volume, for example 2-18.5% by volume, 3-18.5% by volume, 3-18.5% by volume, 4-18.5% by volume, 5-18.5% by volume, 6 ~18.5% by volume, 7-18.5% by volume, 9-18.5% by volume, and the like. In the present invention, the higher the hydrogen gas concentration is below the explosion limit (18.5% by volume or less, preferably 10% by volume or less), the effect of improving the symptoms of the aftereffects of viral infection and / or the effect of suppressing the deterioration of symptoms. tends to be large.

Since hydrogen is a combustible and explosive gas, in improving the symptoms of the aftereffects of viral infections and/or suppressing the worsening of the symptoms, it is included in the composition of the present invention under safe conditions. It is preferably administered to patients with sequelae. For example, when the gas other than hydrogen gas is air, the concentration of air is, for example, in the range of 81.5 to 99.5% by volume.

When the gas other than hydrogen gas contains oxygen gas, the oxygen gas concentration is, for example, in the range of 21 to 99.5% by volume.
Nitrogen gas can be contained as another main gas. A gas such as carbon dioxide, which is a gas contained in the air, may be contained in an amount about the amount present in the air.
In the present invention, a hydrogen-dissolved liquid can be administered to a patient suffering from aftereffects of a viral infection, or the patient can be made to ingest the hydrogen-dissolved liquid in combination with the administration of the hydrogen gas-containing gas, if necessary.

When co-administered with a hydrogen-dissolved liquid, the composition of the present invention can be administered prior to the administration of the hydrogen-dissolved liquid, simultaneously with the administration of the hydrogen-dissolved liquid, or after the administration of the hydrogen-dissolved liquid.
Specifically, the hydrogen-dissolved liquid is an aqueous liquid in which hydrogen gas is dissolved. Here, the aqueous liquid includes, but is not limited to, water (e.g., sterilized water, purified water), physiological saline, and buffer solution. (eg, pH 4-7.4 buffer solution), ethanol-containing water (eg, ethanol content 0.1-2% by volume), infusion solution, infusion solution, injection solution, beverage, and the like. The hydrogen concentration of the hydrogen-dissolved liquid is, for example, 1 to 10 ppm, for example, 2 to 8% by volume, 3 to 7% by volume, 3 to 6% by volume, 4 to 6% by volume, 4 to 5% by volume, 5 to 10% by volume, 5 to 8% by volume, 6 to 8% by volume, 6 to 7% by volume, etc., more preferably 5 to 8% by volume, for example 6 to 8% by volume, 6 to 7% by volume, etc. In the present invention, there is a tendency that the higher the hydrogen gas concentration is below the explosion limit, the greater the effect of improving the symptoms of aftereffects of viral infection and/or suppressing the worsening of the symptoms.

A drug for treating the aftereffects of viral infection may be added to the hydrogen-dissolved liquid. Alternatively, the medicament may be administered separately from the administration of the hydrogen-dissolved liquid or hydrogen gas-containing gas.
After the hydrogen gas-containing gas or hydrogen-dissolved liquid is blended so as to have a predetermined hydrogen gas concentration, for example, a pressure-resistant container (for example, a stainless steel cylinder, an aluminum can, preferably the inside is laminated with an aluminum film, a pressure-resistant It is filled in a plastic bottle (for example, a pressure-resistant PET bottle), a plastic bag, an aluminum bag, etc.). Aluminum has the property that it is difficult for hydrogen molecules to permeate through it. Alternatively, the hydrogen gas-containing gas or hydrogen-dissolved liquid is administered at the time of administration using a hydrogen gas generator, a hydrogen water generator, or a hydrogen gas addition device, such as a known or commercially available hydrogen gas supply device (for generating a hydrogen gas-containing gas). device), hydrogen adding device (hydrogen water generating device), non-destructive hydrogen adding device (e.g., device for non-destructively adding hydrogen gas to the inside of the bag of biologically applicable liquid such as infusion solution) may be made in situ.
The hydrogen gas supply device mixes the hydrogen gas generated by the reaction between the hydrogen generating agent (e.g., metal aluminum, magnesium hydride, etc.) and water and the diluent gas (e.g., air, oxygen, etc.) at a predetermined ratio. (Japanese Patent No. 5228142, etc.). Alternatively, hydrogen gas generated by electrolysis of water is mixed with a diluent gas such as oxygen or air (Japanese Patent No. 5502973, Japanese Patent No. 5900688, etc.). Thereby, a hydrogen gas-containing gas having a hydrogen concentration within the range of 0.5 to 18.5% by volume can be prepared.

The hydrogenation device is a device that generates hydrogen using a hydrogen generating agent and a pH adjuster and dissolves it in a biologically applicable liquid such as water (Japanese Patent No. 4756102, Japanese Patent No. 4652479, Japan Japanese Patent No. 4950352, Japanese Patent No. 6159462, Japanese Patent No. 6170605, Japanese Patent Application Laid-Open No. 2017-104842, Japanese Patent No. 6159462, etc.). Combinations of the hydrogen generating agent and the pH adjuster include, for example, metallic magnesium and a strongly acidic ion exchange resin or organic acid (eg, malic acid, citric acid, etc.), metallic aluminum powder and calcium hydroxide powder, and the like. As a result, a hydrogen-dissolved liquid having a dissolved hydrogen concentration of about 1 to 10 ppm can be prepared (for example, trade name "Seven Water" (Quasia), etc.).

A non-destructive hydrogen adding device is a device or device that adds hydrogen molecules to commercially available liquids such as intravenous fluids (for example, enclosed in a hydrogen-permeable plastic bag such as a polyethylene bag) from the outside of the package. and is commercially available from, for example, MiZ (http://www.e-miz.co.jp/technology.html). In this device, by immersing a bag containing a fluid applicable to a living body in saturated hydrogen water, hydrogen permeates the bag and aseptically dissolves hydrogen in the fluid applicable to a living body until concentration equilibrium is reached. The device is composed of, for example, an electrolytic cell and a water tank, and water in the water tank circulates through the electrolytic cell and the water tank, and can generate hydrogen by electrolysis. Alternatively, simple disposable instruments can be used for the same purpose (Japanese Patent Application Laid-Open No. 2016-112562, etc.). This device contains a plastic bag (hydrogen permeable bag, such as a polyethylene bag) containing a biologically applicable fluid and a hydrogen generating agent (such as metallic calcium, metallic magnesium/cation exchange resin, etc.) inside an aluminum bag. The hydrogen generating agent is wrapped in, for example, a non-woven fabric (eg, a water vapor permeable non-woven fabric). Hydrogen generated by wetting the hydrogen generating agent wrapped in the non-woven fabric with a small amount of water such as steam permeates the plastic bag and is nondestructively and aseptically dissolved in the biologically applicable liquid.
Hydrogen gas-containing gas and hydrogen-saturated biocompatible fluids (e.g., sterile water, physiological saline, intravenous fluids, etc.) prepared using the above devices or instruments can be administered orally to patients with sequelae of viral infections or It can be administered parenterally.
Another form of the composition of the present invention is an agent containing a hydrogen generating agent capable of generating hydrogen in the gastrointestinal tract, which is prepared for oral administration (or ingestion) to a patient suffering from the aftereffects of a viral infection. Forms (eg, tablets, capsules, etc.) are included. The hydrogen generating agent is preferably composed of ingredients approved as food or food additives, for example.

3. Improvement of symptoms of sequelae of viral infection and/or suppression of exacerbation of symptoms at least pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, slight fever, muscle pain, hypoesthesia, arthralgia, chest discomfort, chest pain, sore throat, headache, dull headache, body pain, general pain, weakness, cognitive impairment, memory impairment, language search difficulties, gastrointestinal disorders, abdominal pain, poor concentration, dizziness when standing up, weakness, irregularity abnormal body temperature, chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, tinnitus, confusion, sleep disturbance, lightheadedness, dizziness, loss of appetite, weakness Methods are provided for ameliorating and/or inhibiting the exacerbation of symptoms, including hypersensitivity, bradycardia, hypotension, nausea, persistent cough, brain fog, rashes, and/or decreased activity levels associated with these symptoms.

The compositions of the present invention allow improvement of the patient's QOL (quality of life).
As a method of administering the composition of the present invention to a patient suffering from the aftereffects of a viral infection, when hydrogen gas is used as an active ingredient, transpulmonary administration such as inhalation or inhalation is preferred. When a gas is inhaled, it can be inhaled through the mouth or nose through a nasal cannula or a mask-type device that covers the mouth and nose and is delivered to the lungs for systemic delivery via the blood.

When the hydrogen-dissolved liquid is administered to a patient, oral administration, intravenous administration, or intraarterial administration (including drip infusion) is preferred. Hydrogen-dissolved liquids for oral administration are preferably stored at a low temperature, and the liquids may be cooled or stored at room temperature and administered to patients suffering from the aftereffects of viral infections. It is known that hydrogen dissolves in water at a concentration of about 1.6 ppm (1.6 mg/L) under normal temperature and normal pressure, and the solubility difference due to temperature is relatively small. Alternatively, when the hydrogen-dissolved liquid is, for example, in the form of a drip or injection containing hydrogen gas prepared using the above-described nondestructive hydrogen-containing device, parenteral administration such as intravenous administration and intraarterial administration Depending on the route of administration, it may be administered to patients with sequelae of viral infections.
A hydrogen gas-containing gas having the above hydrogen concentration or a hydrogen-dissolved liquid having the above dissolved hydrogen concentration once or multiple times (eg, 2 to 3 times) per day for a period of 1 week to 3 months or more, such as 1 week to It can be administered to patients with sequelae of viral infections for 6 months or longer. When the hydrogen gas-containing gas is administered, it can be administered for, for example, 10 minutes to 2 hours or more, preferably 20 minutes to 40 minutes or more, more preferably 30 minutes to 2 hours. In addition, when a hydrogen gas-containing gas is transpulmonally administered by inhalation, inhalation, etc., it is under an atmospheric pressure environment or, for example, in a range exceeding standard atmospheric pressure (about 1.013 atmospheres) and 7.0 atmospheres or less. High pressure within, for example, 1.02 to 7.0 atmospheres, preferably 1.02 to 5.0 atmospheres, more preferably 1.02 to 4.0 atmospheres, more preferably 1.02 to 1.35 atmospheres The gas can be administered to a patient suffering from the aftereffects of a viral infection under an internal hyperbaric environment. Administration under a hyperbaric environment can promote the absorption of hydrogen into the body of patients suffering from the aftereffects of viral infections.
The high-pressure environment is capable of injecting, for example, the hydrogen gas-containing gas (e.g., hydrogen-containing oxygen or air) into the interior to form a high pressure that exceeds the standard atmospheric pressure and is 7.0 atmospheres or less. , can be made through the use of a hyperbaric enclosure (eg, a capsule-like enclosure) designed to have sufficient strength. Since the shape of the high-pressure housing is pressure resistant, it is preferable that the entire shape is rounded without corners. Moreover, the material of the high-pressure housing is preferably lightweight and high-strength, and examples thereof include reinforced plastics, carbon fiber composite materials, titanium alloys, and aluminum alloys. Patients with sequelae of viral infection should be administered a composition containing hydrogen gas together with oxygen gas or air in the hyperbaric enclosure to improve symptoms and/or suppress exacerbation of symptoms of sequelae of viral infection. Can receive.

When treating the sequelae of viral infections with the composition of the present invention, a hydrogen gas generator, a hydrogen water generator, or a hydrogen gas addition device (for example, the above-mentioned hydrogen Gas supply device (or gaseous hydrogen inhaler), hydrogen adding device (or hydrogen water generator), non-destructive hydrogen container It is desirable to use a device such as a device that dissolves hydrogen gas).

The present invention will be described in more detail with reference to the following examples, but the technical scope of the present invention is not limited to these examples.

Improving aftereffects of viral infections and/or suppressing worsening of symptoms due to inhalation of hydrogen gas

<Case 1>
(1) Patient's medical condition The patient is a Japanese male, 58 years old as of 2021. In 2021, I was infected with the coronavirus delta strain. Although the patient was cured after treatment at home, the activity level was lower than that of a healthy person, and fatigue, pain, and thinking ability were extremely advanced, and the level of daily living was lower than that of a healthy person. received. The diagnosis based on the doctor's diagnostic criteria was as follows.
(1) Fatigue - Fatigue marked enough to significantly impair endurance and activity level: Severity 3 (severe)
(2) Fatigue after exertion - loss of physical and mental endurance, fatigue exacerbated by physical exertion: severity 3 (severe)
(3) Recovery from exertion takes a long time - more than 24 hours to recover to pre-exertional activity level: severity 2 (moderate)
▲ 4 ▼ Pain - muscle pain, joint pain, headache: severity 2 (moderate)
(5) Sleep disorders - nonrestorative sleep, insomnia, hypersomnia: severity 2 (moderate)
(6) Confusion and loss of concentration: severity 2 (moderate)
▲ 7 ▼ Memory impairment-short-term memory is impaired: severity 1 (mild)
(8) Shortness of breath with exertion: severity 2 (moderate)
▲ 9 ▼ Gastrointestinal disorders - diarrhea, irritable bowel syndrome: severity 1 (mild)
(10) Repeated sore throat: severity 1 (mild)
(11) Vertigo or weakness when standing: severity 1 (mild)
(12) Heat/cold intolerance: severity 1 (mild)
(13) Changes in body temperature, irregular body temperature, cold hands and feet: severity 1 (mild)

(2) Hydrogen gas inhalation effect two weeks after the start of inhalation From July 7, 2020, MiZ Co., Ltd. (Ofuna, Kamakura City) hydrogen gas inhaler (Jobs-α, hydrogen concentration about 4% to 5%, 100% Hydrogen gas suction was started using a hydrogen generation rate of 200 ml/min. Three days after the start of hydrogen inhalation, I caught a cold for several days, and the inhalation time was sometimes less than 3 hours, but I inhaled about 3 hours a day.
Before inhaling hydrogen, he had a dull head. It's been years since I've felt like my brain fog has lifted. The frequency of headaches and general pain also seemed to decrease, and the frequency of taking analgesics decreased.
Before inhalation, the sympathetic nerves were high, but after inhaling hydrogen, there was a feeling of relaxation and drowsiness began to appear.

(3) Effect of hydrogen gas inhalation after 4 weeks from the start of inhalation (i) The symptoms for which remarkable recovery was observed based on the diagnosis by a doctor are listed below. Fatigue after exertion - physical Loss of physical and mental endurance, fatigue exacerbated by physical exertion: before inhalation (severity 3: severe) → after inhalation (severity 2: moderate)
Longer recovery from exertion - 24 hours or more to recover to pre-exertional activity level: before inhalation (severity 2: moderate) → after inhalation (severity 1: mild)
・Fatigue - Persistence, fatigue marked enough to significantly impair activity level: before inhalation (severity 3: severe) → after inhalation (severity 1: mild or severity 2: moderate)
・Pain, headache: before inhalation (severity 2: moderate) → after inhalation (severity 1: mild)
・Decrease in concentration: before inhalation (severity 2: moderate) → after inhalation (severity 1: mild)
・Recurrent sore throat: before inhalation (severity 2: moderate) → after inhalation (severity 1: mild)
Since other symptoms did not worsen, it is considered that the deterioration was suppressed by hydrogen.

(ii) Patient's impression of chronic severe fatigue The inhalation of hydrogen gas greatly relieves the patient's chronic and intense fatigue that makes him bedridden. Even now, sudden intense fatigue after exertion sometimes occurs, but if you inhale hydrogen for about 90 minutes, you can avoid the state of falling asleep one to two hours after exertion.
In general, the degree of fatigue differed depending on the day, and although he still fell asleep on two or three days a week, his condition improved to the point that he felt better on more than half of the days, like healthy subjects.

(iii) Patient's feelings about physical pain Before hydrogen inhalation, headache occurred once or twice a week, but after starting hydrogen inhalation, the frequency of headache decreased significantly, and headache almost disappeared. stopped happening. After hydrogen inhalation, the frequency of taking analgesics decreased to 1/4 of that before hydrogen inhalation. Since last year before I started inhaling hydrogen gas, in order to recover my physical strength and muscle strength, I have been doing muscle training and aerobic exercise on days when my condition is good, which also serves as rehabilitation. I had severe joint pain and needed to take pain relievers. Two weeks after starting hydrogen inhalation, these pains were greatly alleviated. Even when pain occurred due to training, the pain almost disappeared the next day with about 90 minutes of hydrogen inhalation every day. As for the pain in my body, I feel amazing effects.

(iv) Patients' impressions of brain fog The chief complaints of the disease are deterioration of cognition, memory, and concentration. Before inhaling hydrogen gas, it was very painful to do anything, and I always endured and forced myself to do it, but now after starting hydrogen inhalation, my head is clear. As for cognitive ability, I feel that my ability to write sentences and organize materials has returned to its original state.
Occasionally, after one to two hours of desk work, a strong feeling of fatigue suddenly appears, and symptoms such as being unable to speak or understand sentences may appear. Before the start of hydrogen inhalation, such symptoms did not improve easily. However, with hydrogen inhalation, such fatigue, like body pain, disappeared in a short time (2 to 3 hours) compared to before hydrogen inhalation.

(v) Summary of symptoms Hydrogen is clearly effective for chronic fatigue, pain, and brain fog.
Although there are still strong symptoms of post-exertional fatigue and sleep disturbance, the degree of post-exertional fatigue disappearing in 2 to 3 hours by hydrogen inhalation is increasing. These improvements are astounding results given the several years of continued ill health. Although I still have severe symptoms of sleep disturbance, I have never experienced drowsiness after hydrogen inhalation.
For symptoms in which inflammation can be alleviated immediately by hydrogen, it seems to lead to relatively early improvement and/or suppression of exacerbation of symptoms.

<Case 2>
A 43-year-old woman who was infected with the Omicron strain of coronavirus in a PCR test in 2021 recovered from the pneumonia caused by the coronavirus, and although the PCR test was negative, the aftereffects of the coronavirus pneumonia remained. Before inhaling hydrogen gas, she was unable to stand up, stand, or sit due to severe impairment of upper and lower limb function and impairment of trunk function. Was. In addition, symptoms such as general pain, dyspnea due to pulmonary fibrosis, weakness, malaise, fatigue after exertion, sleep disturbance, slight fever, bradycardia, and decreased blood pressure were exhibited.
Inhaled hydrogen gas for 6 hours a day from mid-December 2021 (hydrogen gas inhaler: MiZ Co., Ltd. (Ofuna, Kamakura City), Jobs-α, hydrogen concentration about 4% to 5%, 100% hydrogen generation amount 200ml/ min). As a result, sleep disorder was improved from about 3 days after inhalation, and daily headache and migraine that occurred several times a day were alleviated. Even after 3 weeks, hydrogen gas inhalation relieved symptoms before hydrogen gas inhalation, such as general pain, dyspnea, weakness, malaise, fatigue after exertion, sleep disturbance, slight fever, bradycardia, and decreased blood pressure. The effect continues, and the state of fibrosis in the lungs is also improving.

<Case 3>
A 20-year-old woman who was infected with influenza virus type A in December 2020 was cured of the flu, but showed sequelae such as shortness of breath, dizziness, fatigue, decreased thinking ability and motivation, and headache, and slept most of the day. I was spending my time
Inhaled hydrogen gas for 5 hours a day from early January 2021 (hydrogen gas inhaler: MiZ Co., Ltd. (Ofuna, Kamakura City), Jobs-α, hydrogen concentration about 4% to 5%, 100% hydrogen generation amount 200ml/ min).
As a result, from about 3 weeks after inhalation, the body felt a little lighter, showing improvement in bowel movement and decreased motivation. Also, nap time has decreased. Even after 8 weeks, the number of days without a nap increased, and despite feeling tired, the amount of time for physical activity increased. He also responded that he felt he was heading in the right direction. After that, we confirmed the effect of alleviating symptoms such as shortness of breath, dizziness, fatigue, loss of thinking ability and motivation, and headache before inhaling hydrogen gas.

The present invention can be used to treat symptoms of the aftereffects of a viral infection, such as pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, and slight fever, simply by administering hydrogen to patients with the aftereffects of a viral infection. , muscle pain, hypoesthesia, arthralgia, chest discomfort, chest pain, sore throat, headache, dull headache, body pain, general pain, weakness, cognitive impairment, memory impairment, language search difficulty, gastrointestinal disorder, Abdominal pain, difficulty concentrating, dizziness on standing, weakness, irregular body temperature, chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, tinnitus , confusion, sleep disturbance, lightheadedness, dizziness, loss of appetite, weakness, bradycardia, hypotension, nausea, persistent cough, brain fog, rash, and/or reduced activity level associated with these symptoms. Allows improvement and/or suppression of exacerbation of symptoms. Since hydrogen itself has no known side effects, the QOL of patients can be improved.

Claims (6)

A composition for ameliorating symptoms and/or suppressing aggravation of symptoms of aftereffects of viral infection in patients with aftereffects of viral infection, comprising a hydrogen gas-containing gas as an active ingredient. The virus of the viral infection is coronavirus, novel coronavirus, influenza virus, norovirus, cytomegalovirus, yellow fever virus, herpes virus, measles virus, rubella virus, varicella virus, Ebola virus, Marburg virus, adenovirus, papilloma virus. 2. The composition of claim 1, wherein the virus is one or more viruses selected from the group consisting of viruses, immunodeficiency virus, hepatitis B virus, hantavirus, and variants of these viruses. Symptoms of sequelae of the virus infection include at least pulmonary fibrosis, fatigue, malaise, shortness of breath, dyspnea, palpitations, muscle weakness, slight fever, muscle pain, hypoesthesia, arthralgia, chest discomfort, and chest pain. , sore throat, headache, dull headache, body pain, general pain, weakness, cognitive impairment, memory impairment, language search difficulty, gastrointestinal disorder, abdominal pain, poor concentration, dizziness when standing up, weakness, irregular body temperature , chills, hair loss, cold hands and feet, heat and/or cold intolerance, sweating, hot flushes, lymph node tenderness, significant weight fluctuations, ringing in the ears, confusion, sleep disturbance, lightheadedness, dizziness, loss of appetite, weakness, 3. The composition of claim 1 or 2, comprising bradycardia, hypotension, nausea, persistent cough, brain fog, rash, and/or decreased activity level associated with these conditions. 4. The composition of any one of claims 1-3, wherein the hydrogen concentration of the hydrogen gas-containing gas is greater than zero (0) and less than or equal to 18.5% by volume. 5. The composition of any one of claims 1-4, wherein the composition is administered to the patient by inhalation. 6. A method of making the composition of any preceding claim, wherein the composition is made using a hydrogen gas generator.